Moderna's full pipeline may fuel long-term growth.
Investors flocked to Moderna (NASDAQ: MRNA) stock in the early days of the pandemic for one big reason: The company sold one of the world's most-needed products, a coronavirus vaccine. The vaccine ...
They aren't just "pandemic stocks." ...
Zacks Investment Research on MSN
ImmunityBio vs. Moderna: Which biotech has more upside potential?
Both ImmunityBio IBRX and Moderna MRNA are biotech firms that depend largely on the successful commercialization of a single ...
In a blast from the past, COVID-19 vaccine developer Moderna (NASDAQ: MRNA) just made headlines in 2026. Shares jumped up more than 17% on Jan. 13, Moderna's largest single-day up-move in over three ...
Moderna is scaling its mRNA production capabilities and hiring specialized engineers, as its stock surges over 75% YTD amid a shift beyond COVID-19 vaccines.
Moderna stock soared in the early stages of the pandemic, then struggled -- but in recent times, it’s been on the rise. This other biotech has proven itself as a long-term winner. Though Moderna stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results